What the FDA labels say about taking them together
Clobazam and fluvoxamine
Clobazam's FDA label of March 12, 2024 names fluvoxamine in its drug interactions section; fluvoxamine's label does not name clobazam itself but warns about its class (Benzodiazepines). The clobazam label: “Dosage adjustment of ONFI may be necessary when co-administered with strong CYP2C19 inhibitors or moderate CYP2C19 inhibitors (e.g., omeprazole).”
Check it at the source: the clobazam FDA label on DailyMed (effective March 12, 2024, Lundbeck Pharmaceuticals LLC); the fluvoxamine FDA label on DailyMed (effective June 27, 2026, Zydus Pharmaceuticals USA Inc.).
What does the clobazam label say about fluvoxamine?
Clobazam label, drug interactionsDosage adjustment of ONFI may be necessary when co-administered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole) [see Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Sympazan, NDA210833), Aquestive Therapeutics, effective December 1, 2025 (SPL set 5e3d8fcb-aa7d-4822-88fc-4f06264c3242), via openFDA
Source: FDA drug label (Onfi), Lundbeck Pharmaceuticals LLC, effective March 12, 2024 (SPL set de03bd69-2dca-459c-93b4-541fd3e9571c), via openFDA; the full label on DailyMed
What does the fluvoxamine label say about clobazam?
Fluvoxamine's label does not name clobazam itself; it warns about its class (Benzodiazepines):
Fluvoxamine label, warnings and precautionsBenzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
Fluvoxamine label, warnings and precautionsBenzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.
Source: FDA drug label (Fluvoxamine maleate extended-release), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 6c71d4f6-54b5-4d3a-8d2f-b7773c92c32e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clobazam | Fluvoxamine | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.243 per tablet 10 mg tablet | $4.08 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once